Novo Nordisk A/S (NVO) Projected to Announce Quarterly Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) is expected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.7680 per share and revenue of $10.8912 billion for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. On average, analysts expect Novo Nordisk A/S to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $50.89 on Wednesday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The firm has a fifty day simple moving average of $46.60 and a 200 day simple moving average of $45.59. The stock has a market capitalization of $227.22 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 4.53 and a beta of 0.77. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Transamerica Financial Advisors LLC lifted its position in shares of Novo Nordisk A/S by 201.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after buying an additional 403 shares during the last quarter. Johnson Financial Group Inc. boosted its position in Novo Nordisk A/S by 128.0% during the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after purchasing an additional 384 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in Novo Nordisk A/S during the fourth quarter worth $41,000. Quattro Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $44,000. Finally, State of Wyoming lifted its stake in shares of Novo Nordisk A/S by 72.7% during the 2nd quarter. State of Wyoming now owns 950 shares of the company’s stock worth $66,000 after buying an additional 400 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Five analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.